Press release - 07/01/2021 CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
Digitalisation in Medicine - 08/12/2020 DiHeSys takes steps towards application Digital Health Systems GmbH (DiHeSys) has completed its founding phase and entered a new stage of development. This is reflected in the arrival of a new managing director, a strategic cooperation and its first pilot projects.https:////www.gesundheitsindustrie-bw.de/en/article/news/dihesys-takes-steps-towards-application
Development of the genomDE genome database - 04/12/2020 Whole genome sequencing for diagnosing rare diseases Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…https:////www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
Press release - 01/12/2020 Novel vaccine trial to activate T-cell responses against SARS-CoV-2 A Phase I clinical trial using a self-developed vaccine against SARS-CoV-2 was initiated today at the University Hospital of Tübingen. In contrast to the currently evaluated vaccine candidates against COVID-19, the vaccine CoVAC1, developed by the Department of Immunology (Director Prof. Hans-Georg Rammensee) at the University of Tübingen, aims specifically at the induction of a T-cell-mediated immune response against SARS-COV-2.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/Novel-vaccine-trial-to-activate-T-cell-responses-against-SARS-CoV-2
Press release - 26/11/2020 New mechanism of action: A small-molecule degrades a cancer-promoting protein by gluing it into filaments “Molecular glue degraders” are a new class of cancer drugs, which “glue” cancer growth-promoting proteins directly to the molecular machinery of a cell’s disposal system, leading to the subsequent degradation of the cancer-driving proteins and anti-tumor activity. Scientists from Heidelberg and USA have now deciphered another mechanism whereby a small molecule can degrade a cancer protein. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-mechanism-action-small-molecule-degrades-cancer-promoting-protein-gluing-it-filaments
Article - 04/11/2020 Rapid coronavirus test delivers results in 43 minutes The Hahn-Schickard Institute and Spindiag GmbH in Freiburg im Breisgau have joined forces to develop a rapid test used at the point of care. The test takes just 43 minutes to show whether a patient is infected with the coronavirus SARS-CoV-2. The rapid test is expected to be given market approval in Germany and the EU during the final quarter of 2020.https:////www.gesundheitsindustrie-bw.de/en/article/news/rapid-coronavirus-test-delivers-results-43-minutes
Atriva Therapeutics - 21/10/2020 COVID-19 pioneer drug in Phase II clinical trial – with double the power The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…https:////www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
Press release - 15/10/2020 Common Vulnerabilities of Coronaviruses International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/common-vulnerabilities-coronaviruses
Press release - 08/10/2020 New class of highly effective inhibitors protects against neurodegeneration Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-class-highly-effective-inhibitors-protects-against-neurodegeneration
Press release - 25/09/2020 Bosch’s new rapid coronavirus test delivers reliable results in 39 minutes Bosch has developed a new rapid test for its Vivalytic analysis device to detect the SARS-CoV-2 pathogen. The test provides a reliable result in 39 minutes and is currently the fastest polymerase chain reaction (PCR) test worldwide.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/boschs-new-rapid-coronavirus-test-delivers-reliable-results-39-minutes
Mosses for pharmaceutical production - 16/09/2020 Factor H as a therapeutic option for viral diseases - including COVID-19 The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.https:////www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
Innovative Therapies - 20/08/2020 Labor Dr. Merk is fully committed to viral therapies Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…https:////www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
Press release - 11/08/2020 Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
Press release - 28/07/2020 Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received regulatory approval to start a clinical phase II trial with asunercept in COVID-19 patients in Russia. The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-start-european-clinical-phase-ii-trial-asunercept-covid-19-patients
Press release - 17/06/2020 CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-Receives-Regulatory-Approval-from-German-and-Belgian-Authorities-to-Initiate-Phase-1-Clinical-Trial-of-its-SARS-CoV-2-Va
Vaccine development - 02/06/2020 CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine? All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…https:////www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
Press release - 14/05/2020 CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2).https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-coronavirus-impfstoffkandidat-zeigt-dank-optimierter-mrna-plattform-positive-praeklinische-ergebnisse-bei-niedriger-dos
Press release - 04/05/2020 CorTec is again Germany’s Most Innovative Company For the third time in a row CorTec is ranked among the most innovative companies in Germany. Statista has been conducting out the survey since 2014 and has joined forces with German business magazine Capital for the first time this year for the award. Together with 14 other companies in the medical devices industry, CorTec is entitled to carry the title “Germany’s Most Innovative Company” in this segment.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/CorTec-is-again-Germany-s-Most-Innovative-Company
Press release - 08/04/2020 New Alliance in the Fight Against Coronavirus and COVID-19 Scientists from Heidelberg and Mannheim launch research and development task forcehttps:////www.gesundheitsindustrie-bw.de/en/article/press-release/allianz-im-kampf-gegen-coronavirus-und-covid-19
Press release - 24/03/2020 State aid: Commission approves €300 million Luxembourg scheme to support companies affected by coronavirus outbreak The European Commission has found Luxembourg's €300 million scheme to support companies affected by the coronavirus outbreak to be in line with EU State aid rules. The scheme was approved under the State aid Temporary Framework to support the economy in the context of the COVID-19 outbreak adopted by the Commission on 19 March 2020.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/state-aid-commission-approves-eur300-million-luxembourg-scheme-support-companies-affected-coronavirus-outbreak
Funding Novartis announces broad range of initiatives to respond to COVID-19 Pandemic Funding programme, Funded by: Novartis AGhttps:////www.gesundheitsindustrie-bw.de/en/database/funding/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic
Press release - 16/03/2020 CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed today that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-focuses-on-the-development-of-mRNA-based-coronavirus-vaccine-to-protect-people-worldwide
Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Waiting for a SARS-CoV-2 vaccine Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.https:////www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
Article - 22/10/2019 Using CAR T cells for treating cancer After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.https:////www.gesundheitsindustrie-bw.de/en/article/news/using-car-t-cells-for-treating-cancer
Freiburg im Breisgau - 04/06/2019 Spindiag’s continued road to success: Expansion of Series A with an additional 4 million euros for market entry Spindiag, a young medtech company in the German state of Baden-Württemberg, announced today the expanded financing of its first Series A. Based on a proprietary microfluidic technology first researched at the company’s mother institute Hahn-Schickard, Spindiag is developing a sustainable platform to diagnose infections and, as a first product, a rapid test for multidrug-resistant bacteria.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/spindiags-continued-road-to-success-expansion-of-series-a-with-an-additional-4-million-euros-for-market-entry